CRO Solutions Launches VxP Pharma

CRO Solutions, Inc. has launched VxP Pharma, Inc. as a wholly owned subsidiary comprised of the combined services of its independently owned and operated “niche” CROs. VxP Pharma will offer pharma development services, as well as technical support, for the development and production of drugs, diagnostics, and drug/device combination products, from discovery through Phase IIb.

The majority of VxP Pharma’s Labs are located in the U.S., although the group also has facilities in Europe and Asia. All VxP sites have been fully audited by CRO Solutions/VxP Pharma, as well as by global pharmaceutical and biotechnology clients. Most sites have also been audited by the U.S. FDA as well as other international regulatory agencies.

VxP Pharma’s chief executive officer, Raymond E. Peck, commented, “Pharmaceutical and biotech research scientists throughout the industry tell us that they prefer to work with smaller, focused CROs, rather than with the huge multinational ‘one-size-fits-all’ CROs. For these people, VxP Pharma is a perfect fit because we offer a single point of contact, as well as the confidence that, if you work with VxP, you are working with a state-of-the-art lab that has been subject to a complete audit, including, in most cases, an audit by the FDA. Because VxP consists of smaller, independently owned and operated facilities who focus on only one area of drug development, our drug development clients get all the advantages of working directly with a specialist ‘niche’ CRO, including being able to work with some of the best subject matter experts in the industry.”